Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
William Sikov, MD, associate director of Clinical Research, Program in Women
William Sikov, MD, associate director of Clinical Research, Program in Women’s Oncology, Women and Infants Hospital of Rhode Island, on the phase II CALGB 40603 trial, which tested if standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab would result in a pathologic complete response in patients with stage II/III triple-negative breast cancer.
Articles in this issue
Glembatumumab and the Phase IIb Registrational METRIC Trial: Q&A With Denise Yardley, MD, and Linda Vahdat, MD
Survival Improved Over 10 Years With Breast-Conserving Therapy Versus Mastectomy
Dr. Carey Anders on Treating Brain Metastases in Breast Cancer
Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment
Dr. Matthew J. Ellis on Neoadjuvant Palbociclib in Primary Breast Cancer
Avelumab Shows Efficacy in PD-L1-Positive Metastatic Breast Cancer
The Complications and Costs in Mastectomies and Lumpectomies in Early Breast Cancer
Study Links pCR Post-Neoadjuvant Therapy to Increased Survival Rates in TNBC
Recent Videos
Related Content
